Table of Contents Author Guidelines Submit a Manuscript
International Journal of Otolaryngology
Volume 2017, Article ID 5185268, 5 pages
https://doi.org/10.1155/2017/5185268
Research Article

Absence of Relationship between Mitochondrial DNA Haplogroups and Cisplatin-Induced Hearing Loss

1Otolaryngology Department, Hospital Vall d’Hebron, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain
2Biomedical Research in Cancer Stem Cells, Pathology Department, Hospital Vall d’Hebron, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain
3Oncology Department, Hospital Vall d’Hebron, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain
4Anaesthesiology and Resuscitation Department, Hospital Vall d’Hebron, Passeig Vall d’Hebron 119-129, 08035 Barcelona, Spain
5Group of Mitochondrial Dysfunction and Diseases, International Clinical Research Center and St. Anne’s University Hospital Brno, Brno, Czech Republic

Correspondence should be addressed to J. Lorente; ten.norbehv@etnerolj

Received 23 January 2017; Revised 1 May 2017; Accepted 18 May 2017; Published 3 July 2017

Academic Editor: Leonard P. Rybak

Copyright © 2017 D. Graterol et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. A. Underhill and T. Kivisild, “Use of y chromosome and mitochondrial DNA population structure in tracing human migrations,” Annual Review of Genetics, vol. 41, pp. 539–564, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. H. K. Lee, Y. M. Cho, S. H. Kwak, S. Lim, K. S. Park, and E. B. Shim, “Mitochondrial dysfunction and metabolic syndrome-looking for environmental factors,” Biochimica et Biophysica Acta - General Subjects, vol. 1800, no. 3, pp. 282–289, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. E. C. Ienco, C. Simoncini, D. Orsucci et al., “May ‘mitochondrial eve’ and mitochondrial haplogroups play a role in neurodegeneration and alzheimer's disease?” International Journal of Alzheimer's Disease, vol. 2011, Article ID 709061, 11 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. C. M. Hagen, F. H. Aidt, P. L. Hedley et al., “Mitochondrial haplogroups modify the risk of developing hypertrophic cardiomyopathy in a Danish population,” PLoS ONE, vol. 8, no. 8, Article ID e71904, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Gaweda-Walerych and C. Zekanowski, “The impact of mitochondrial DNA and nuclear genes related to mitochondrial functioning on the risk of Parkinson's disease,” Current Genomics, vol. 14, no. 8, pp. 543–559, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. F. J. Blanco, I. Rego, and C. Ruiz-Romero, “The role of mitochondria in osteoarthritis,” Nature Reviews Rheumatology, vol. 7, no. 3, pp. 161–169, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. P.-W. Wang, T.-K. Lin, S.-W. Weng, and C.-W. Liou, “Mitochondrial DNA variants in the pathogenesis of type 2 diabetes - Relevance of asian population studies,” Review of Diabetic Studies, vol. 6, no. 4, pp. 237–246, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. V. Varga, P. Ferdinandy, L. Liaudet, and P. Pacher, “Drug-induced mitochondrial dysfunction and cardiotoxicity,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 309, no. 9, pp. H1453–H1467, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Yang, H. Liu, F. Liu, and Z. Dong, “Mitochondrial dysregulation and protection in cisplatin nephrotoxicity,” Archives of Toxicology, vol. 88, no. 6, pp. 1249–1256, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. J. H. van den Berg, J. H. Beijnen, A. J. M. Balm, and J. H. M. Schellens, “Future opportunities in preventing cisplatin induced ototoxicity,” Cancer Treatment Reviews, vol. 32, no. 5, pp. 390–397, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. G. Crundwell, P. Gomersall, and D. M. Baguley, “Ototoxicity (cochleotoxicity) classifications: A review,” International Journal of Audiology, vol. 55, no. 2, pp. 65–74, 2016. View at Publisher · View at Google Scholar · View at Scopus
  12. P. R. Brock, K. R. Knight, D. R. Freyer et al., “Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale,” Journal of Clinical Oncology, vol. 30, no. 19, pp. 2408–2417, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. U. Peters, S. Preisler-Adams, C. Lanvers-Kaminsky et al., “Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin,” Anticancer Research, vol. 23, pp. 1249–1255, 2003. View at Google Scholar
  14. S. Rahman, R. Ecob, H. Costello et al., “Hearing in 44-45 year olds with m.1555A>G, a genetic mutation predisposing to aminoglycoside-induced deafness: a population based cohort study,” British Medical Journal Open, vol. 2, Article ID e000411, 2012. View at Google Scholar
  15. A. Torroni, K. Huoponen, P. Francalacci et al., “Classification of European mtDNAs from an analysis of three European populations,” Genetics, vol. 144, pp. 1835–1850, 1996. View at Google Scholar
  16. W. Landier, “Ototoxicity and cancer therapy,” Cancer, vol. 122, no. 11, pp. 1647–1658, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. E. A. Theunissen, C. L. Zuur, and K. Jozwiak, “Prediction of hearing loss due to cisplatin chemoradiotherapy,” JAMA Otolaryngololgy Head & Neck Surgery, vol. 141, pp. 810–815, 2015. View at Publisher · View at Google Scholar
  18. T. F. Spracklen, H. Whitehorn, A. A. Vorster, L. Ramma, S. Dalvie, and R. S. Ramesar, “Genetic variation in otos is associated with cisplatin-induced ototoxicity,” Pharmacogenomics, vol. 15, no. 13, pp. 1667–1676, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Langer, W. Stohr, S. Bielack et al., “Late effects surveillance system for sarcoma patients,” Pediatric Blood Cancer, vol. 42, pp. 373–379, 2004. View at Google Scholar